These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 29933048)

  • 1. Agave negatively regulates YAP and TAZ transcriptionally and post-translationally in osteosarcoma cell lines.
    Ferraiuolo M; Pulito C; Finch-Edmondson M; Korita E; Maidecchi A; Donzelli S; Muti P; Serra M; Sudol M; Strano S; Blandino G
    Cancer Lett; 2018 Oct; 433():18-32. PubMed ID: 29933048
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hippo/YAP signaling pathway is involved in osteosarcoma chemoresistance.
    Wang DY; Wu YN; Huang JQ; Wang W; Xu M; Jia JP; Han G; Mao BB; Bi WZ
    Chin J Cancer; 2016 May; 35():47. PubMed ID: 27206784
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ROCK2 deprivation leads to the inhibition of tumor growth and metastatic potential in osteosarcoma cells through the modulation of YAP activity.
    Zucchini C; Manara MC; Cristalli C; Carrabotta M; Greco S; Pinca RS; Ferrari C; Landuzzi L; Pasello M; Lollini PL; Gambarotti M; Donati DM; Scotlandi K
    J Exp Clin Cancer Res; 2019 Dec; 38(1):503. PubMed ID: 31878963
    [TBL] [Abstract][Full Text] [Related]  

  • 4. S1P/S1PR3 axis promotes aerobic glycolysis by YAP/c-MYC/PGAM1 axis in osteosarcoma.
    Shen Y; Zhao S; Wang S; Pan X; Zhang Y; Xu J; Jiang Y; Li H; Zhang Q; Gao J; Yang Q; Zhou Y; Jiang S; Yang H; Zhang Z; Zhang R; Li J; Zhou D
    EBioMedicine; 2019 Feb; 40():210-223. PubMed ID: 30587459
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long non-coding RNA XIST promotes osteosarcoma progression by targeting YAP via miR-195-5p.
    Yang C; Wu K; Wang S; Wei G
    J Cell Biochem; 2018 Jul; 119(7):5646-5656. PubMed ID: 29384226
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disrupting YAP1-mediated glutamine metabolism induces synthetic lethality alongside ODC1 inhibition in osteosarcoma.
    Wang H; Tao Y; Han J; Shen J; Mu H; Wang Z; Wang J; Jin X; Zhang Q; Yang Y; Lin J; Sun M; Ma X; Ren L; LeBlanc AK; Xu J; Hua Y; Sun W
    Cell Oncol (Dordr); 2024 Oct; 47(5):1845-1861. PubMed ID: 39115605
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sensitisation of Cancer Cells to MLN8237, an Aurora-A Inhibitor, by YAP/TAZ Inactivation.
    Oku Y; Nishiya N; Sugiyama S; Sato H; Uehara Y
    Anticancer Res; 2018 Jun; 38(6):3471-3476. PubMed ID: 29848699
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antitumor activity of curcumin is involved in down-regulation of YAP/TAZ expression in pancreatic cancer cells.
    Zhou X; Su J; Feng S; Wang L; Yin X; Yan J; Wang Z
    Oncotarget; 2016 Nov; 7(48):79076-79088. PubMed ID: 27738325
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blocking CXCR4-CARM1-YAP axis overcomes osteosarcoma doxorubicin resistance by suppressing aerobic glycolysis.
    Li Z; Lu H; Zhang Y; Lv J; Zhang Y; Xu T; Yang D; Duan Z; Guan Y; Jiang Z; Liu K; Liao Y
    Cancer Sci; 2024 Oct; 115(10):3305-3319. PubMed ID: 39073190
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ailanthone inhibits cell growth and migration of cisplatin resistant bladder cancer cells through down-regulation of Nrf2, YAP, and c-Myc expression.
    Daga M; Pizzimenti S; Dianzani C; Cucci MA; Cavalli R; Grattarola M; Ferrara B; Scariot V; Trotta F; Barrera G
    Phytomedicine; 2019 Mar; 56():156-164. PubMed ID: 30668336
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Knockdown of HuR represses osteosarcoma cells migration, invasion and stemness through inhibition of YAP activation and increases susceptibility to chemotherapeutic agents.
    Xu W; Chen C; Xu R; Li Y; Hu R; Li Z; Zhu X
    Biomed Pharmacother; 2018 Jun; 102():587-593. PubMed ID: 29597092
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanically tunable coaxial electrospun models of YAP/TAZ mechanoresponse and IGF-1R activation in osteosarcoma.
    Molina ER; Chim LK; Salazar MC; Mehta SM; Menegaz BA; Lamhamedi-Cherradi SE; Satish T; Mohiuddin S; McCall D; Zaske AM; Cuglievan B; Lazar AJ; Scott DW; Grande-Allen JK; Ludwig JA; Mikos AG
    Acta Biomater; 2019 Dec; 100():38-51. PubMed ID: 31542501
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An evaluation of TAZ and YAP crosstalk with TGFβ signalling in canine osteosarcoma suggests involvement of hippo signalling in disease progression.
    Luu AK; Schott CR; Jones R; Poon AC; Golding B; Hamed R; Deheshi B; Mutsaers A; Wood GA; Viloria-Petit AM
    BMC Vet Res; 2018 Nov; 14(1):365. PubMed ID: 30477496
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of the Hippo pathway transcriptional coactivators YAP/TAZ and β1-integrin in conventional osteosarcoma.
    Bouvier C; Macagno N; Nguyen Q; Loundou A; Jiguet-Jiglaire C; Gentet JC; Jouve JL; Rochwerger A; Mattei JC; Bouvard D; Salas S
    Oncotarget; 2016 Oct; 7(40):64702-64710. PubMed ID: 27608849
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Suppression of YAP by DDP disrupts colon tumor progression.
    Li K; Guo J; Wu Y; Jin D; Jiang H; Liu C; Qin C
    Oncol Rep; 2018 May; 39(5):2114-2126. PubMed ID: 29512779
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Suppressing CHD1L reduces the proliferation and chemoresistance in osteosarcoma.
    Fan GT; Ling ZH; He ZW; Wu SJ; Zhou GX
    Biochem Biophys Res Commun; 2021 May; 554():214-221. PubMed ID: 33813077
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Actin remodeling confers BRAF inhibitor resistance to melanoma cells through YAP/TAZ activation.
    Kim MH; Kim J; Hong H; Lee SH; Lee JK; Jung E; Kim J
    EMBO J; 2016 Mar; 35(5):462-78. PubMed ID: 26668268
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TAZ and YAP are frequently activated oncoproteins in sarcomas.
    Fullenkamp CA; Hall SL; Jaber OI; Pakalniskis BL; Savage EC; Savage JM; Ofori-Amanfo GK; Lambertz AM; Ivins SD; Stipp CS; Miller BJ; Milhem MM; Tanas MR
    Oncotarget; 2016 May; 7(21):30094-108. PubMed ID: 27129148
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of nuclear factor-κB by dehydroxymethylepoxyquinomicin induces schedule-dependent chemosensitivity to anticancer drugs and enhances chemoinduced apoptosis in osteosarcoma cells.
    Castro-Gamero AM; Borges KS; da Silva Silveira V; Lira RC; de Paula Gomes Queiroz R; Valera FC; Scrideli CA; Umezawa K; Tone LG
    Anticancer Drugs; 2012 Jul; 23(6):638-50. PubMed ID: 22382389
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation of nuclear pIGF-1R/IGF-1R and YAP/TAZ in a tissue microarray with outcomes in osteosarcoma patients.
    Molina ER; Chim LK; Lamhamedi-Cherradi SE; Mohiuddin S; McCall D; Cuglievan B; Krishnan S; Porter RW; Ingram DR; Wang WL; Lazar AJ; Scott DW; Truong DD; Daw NC; Ludwig JA; Mikos AG
    Oncotarget; 2022; 13():521-533. PubMed ID: 35284040
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.